Klaria Year-End Report Q4 2021
Klaria Year-End Report Q4 2021
Summary of the Year-End Report
Promising quarter with registration applications and preparations for additional clinical studies
Fourth quarter of 2021
- Net sales amounted to 0.0 MSEK (0.0 MSEK)
- Other income amounted to 6.2 MSEK (2.0 MSEK)
- R&D costs for the period amounted to 28.1 MSEK (17.6 MSEK)
- Profit after tax amounted to -39.1 MSEK (-17.0 MSEK)
- Earnings per share for the quarter amounted to -0.75 SEK (-0.36 SEK)
- Cash flow from operating activities amounted to -14.6 MSEK (-10.0 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 25.5 MSEK (31.3 MSEK)
- Equity as of December 31 amounted to 69.4 MSEK (109.9 MSEK)
- CDS signs cooperation agreement with Hemply Balance for commercialization of alginate films with CBD in Europe
- At an Extraordinary General Meeting on December 30, the Meeting resolved on a directed new issue of 2,158,678 shares to FFT Medical in accordance with a supplementary agreement signed with the company, whereby the final payment is settled regarding Klaria's acquisition of the shares in Uppsalagruppen AB. The supplementary agreement also means that the final payment of 1 MSEK will be paid in cash. The result effect of the agreement will be 14.3 MSEK.
- At an Extraordinary General Meeting on December 30, the Meeting resolved to issue 5,750,000 warrants to the company, with the intention of being granted to management, employees and consultants. An option can be exercised during the period 2025-01-01—2025-01-31 for one share in the company at an exercise price of SEK 11 per share.
- Klaria has received a third payment of approximately 2.2 MSEK from the EU's Horizon 2020 program for the development of Sumatriptan Alginate Film.
The period January-December 2021
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 37.5 MSEK (8.0 MSEK)
- R&D costs for the period amounted to 63.5 MSEK (48.4 MSEK)
- Profit after tax amounted to -53.5 MSEK (-51.4 MSEK)
- Earnings per share for the period amounted to -1.03 SEK (-1.19 SEK)
- Cash flow from operating activities amounted to -24.8 MSEK (-35.3 MSEK)
- An up-front payment of 30.5 MSEK has been received from Imbrium Therapuetics in connection with the signing of an option agreement regarding the market rights to the drug candidate Adrenalin Alginate film for the treatment of severe allergic reactions.
- Klaria has received a third payment of approximately 2.2 MSEK from the EU's Horizon 2020 program for the development of Sumatriptan Alginate Film.
- Klaria's combination patent for alginate film with Sumatriptan has been approved in the USA.
- Klaria has signed a new financing agreement of 50 MSEK.
- The Pure Jamaican company group and Klaria has signed agreements on R&D and commercialization in Latin America and the Caribbean.
Events after the end of the quarter
- Klaria is granted a combination patent for Sumatriptan Alginate film in Mexico and thus gets exclusivity until 2037.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.